Browsing Tag
PCSK9 inhibitor
5 posts
Amgen’s landmark Repatha trial to take center stage at AHA 2025 with major cardiovascular prevention results
Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025.
Zydus advances PCSK9 inhibitor with Phase I clinical study approval
Zydus, a global pharmaceutical company, has secured permission from CDSCO, India, to kickstart the Phase I clinical study…
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a…
Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab)…
FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food…